Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| Kiniksa Pharmaceuticals IntlCUSIP G52694109 | $58.7M | 11.5% | +20.6% |
| RLAYRelay Therapeutics Inc | $55.8M | 11.0% | |
| LBRXLb Pharmaceuticals Inc | $44.7M | 8.8% | |
| RLMDRelmada Therapeutics Inc | $44.2M | 8.7% | +2.1% |
| ANROAlto Neuroscience Inc | $35.7M | 7.0% | +2.1% |
| DNTHDianthus Therapeutics Inc | $34.6M | 6.8% | −4.9% |
| Alkermes PLCCUSIP G01767105 | $28.5M | 5.6% | +71.0% |
| SVRASavara Inc | $21.3M | 4.2% | +2.1% |
| PCVXVaxcyte Inc | $17.8M | 3.5% | +24.6% |
| ELVNEnliven Therapeutics Inc | $16.7M | 3.3% | |
| ENTAEnanta Pharmaceuticals Inc | $15.9M | 3.1% | +16.7% |
| CATXPerspective Therapeutics Inc | $12.6M | 2.5% | +40.6% |
| Inflarx NvCUSIP N44821101 | $12.0M | 2.4% | New |
| SRZNSurrozen Inc | $11.2M | 2.2% | |
| ALMSAlumis Inc | $11.0M | 2.2% | |
| IPSCCentury Therapeutics Inc | $9.9M | 2.0% | |
| NERVMinerva Neurosciences Inc | $9.2M | 1.8% | |
| SABSSab Biotherapeutics Inc | $8.6M | 1.7% | |
| ANTXAn2 Therapeutics Inc | $8.0M | 1.6% | |
| ERASErasca Inc | $7.7M | 1.5% | |
| IKTInhibikase Therapeutics Inc | $7.3M | 1.4% | |
| Research Alliance Corp IIICUSIP G75226103 | $5.3M | 1.0% | New |
| Helix Acquisition Corp IIICUSIP G4444S107 | $5.3M | 1.0% | |
| ZLABZai Lab Ltd | $5.3M | 1.0% | New |
| ACHVAchieve Life Science Inc | $4.8M | 0.9% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ELVNEnliven Therapeutics Inc | December 31, 2025 | +229.5% | $16.7M |
| IPSCCentury Therapeutics Inc | December 31, 2025 | +146.3% | $9.9M |
| DNTHDianthus Therapeutics Inc | December 31, 2025 | +136.5% | $34.6M |
| RLAYRelay Therapeutics Inc | December 31, 2025 | +121.2% | $55.8M |
| Kiniksa Pharmaceuticals IntlCUSIP G52694109 | December 31, 2025 | +55.0% | $58.7M |
| ANROAlto Neuroscience Inc | December 31, 2025 | +48.3% | $35.7M |
| Alkermes PLCCUSIP G01767105 | March 31, 2026 | +48.2% | $28.5M |
| LBRXLb Pharmaceuticals Inc | December 31, 2025 | +45.8% | $44.7M |
| RLMDRelmada Therapeutics Inc | December 31, 2025 | +43.3% | $44.2M |
| ANTXAn2 Therapeutics Inc | March 31, 2026 | +41.5% | $8.0M |
Sold off last quarter
- Centessa PharmaceuticalsCUSIP 152309100 was $19.5M
- Kalvista PharmaceuticalsCUSIP 483497103 was $18.1M
- MAZEMaze Therapeutics Inc was $6.0M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +19.6% | +14.8% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Spruce Street Capital LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2050194&type=13F-HR&dateb=&owner=include&count=40CIK 2050194
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2050194/000205019426000005/Filed August 13, 2026 · accession 0002050194-26-000005